
follow us
eli lilli compani
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
compani
indianapoli jan /prnewswire/ -- eli lilli compani nyse today announc financi
result fourth quarter full year
certain financi inform present report non-gaap basi
number press releas may add due round report result prepar accord
gener accept account principl includ revenu expens recogn period
reflect elanco discontinu oper period present non-gaap measur
reflect adjust item describ reconcili tabl later releas assum
disposit elanco occur begin period present includ benefit reduct
share common stock outstand compani financi guidanc provid report
non-gaap basi non-gaap measur present provid addit insight underli
trend compani busi
lilli earli phase excit period growth compani combin strong revenu growth
newer medicin prudent expens control across busi enabl lilli invest
pipelin still deliv impress earn growth fourth quarter full-year said david rick
lilli chairman ceo look forward continu progress scientist work expand
portfolio innov medicin offer new treatment option patient area diabet oncolog
immunolog neurosci
event last three month
 food drug administr fda grant prioriti review new drug applic selpercatinib
treatment patient advanc ret fusion-posit non-smal cell lung cancer nsclc ret-mut
medullari thyroid cancer ret fusion-posit thyroid cancer
fda approv trijardi xr empagliflozin/linagliptin/metformin hydrochlorid extend releas tablet lower
blood sugar adult type diabet along diet exercis trijardi xr provid three type diabet
medicin one pill includ jardianc empagliflozin tradjenta linagliptin metformin hydrochlorid
european commiss approv new indic associ label updat cyramza new label
includ indic cyramza combin erlotinib first-lin treatment adult patient
metastat nsclc activ epiderm growth factor receptor egfr mutat
european commiss approv baqsimi glucagon nasal powder mg treatment sever
hypoglycemia peopl diabet age four year
compani announc baricitinib met primari endpoint two phase studi
evalu safeti efficaci baricitinib combin topic corticosteroid treatment adult
patient moder
intoler
sever atop dermat
contraind treatment cyclosporin evalu safeti efficaci baricitinib
treatment adult patient moder sever atop dermat
compani innov biolog inc announc result phase studi china tyvyt
combin alimta platinum first-lin advanc recurr nonsquam nsclc without sensit
egfr mutat rearrang met predefin primari endpoint progression-fre surviv interim
compani boehring ingelheim announc result two phase clinic trial relat function
endpoint jardianc adult chronic heart failur reduc preserv eject fraction
trial signific chang baselin week exercis abil jardianc versu placebo
measur six-minut walk test primari endpoint studi safeti profil seen
trial similar current known safeti profil jardianc new safeti risk identifi
compani announc definit agreement acquir dermira inc per share approxim
billion all-cash transact dermira biopharmaceut compani dedic develop new therapi
chronic skin condit pend acquisit expand lilli immunolog pipelin addit
lebrikizumab novel investig monoclon antibodi design bind high affin
evalu phase clinic develop program treatment moderate-to-sever atop dermat
adolesc adult patient age year older pend acquisit dermira also expand lilli
portfolio market dermatolog medicin addit qbrexza medic cloth approv
fda topic treatment primari axillari hyperhidrosi uncontrol excess underarm sweat
compani announc plan add two cost-sav option suit solut peopl
use lilli insulin introduc lower-pr version humalog kwikpen humalog junior
kwikpen insulin percent lower list price compar brand version avail
mid-april lilli first lower-pr insulin insulin lispro inject made avail may percent
lower list price humalog decemb nearli peopl fill prescript insulin lispro inject
approxim percent peopl use humalog util lower-pr option insulin
lispro inject distribut major wholesal order pharmaci
 district court southern district indiana rule favor lilli alimta vitamin regimen patent
would infring competitor state intent market altern salt form pemetrex prior
patent expir rule came case eli lilli compani apotex inc apotex file
compani announc global commerci agreement integr inc product lilli
person diabet manag system current develop advanc treatment diabet
term non-exclus agreement lilli use continu glucos monitor cgm devic
pen- pump-bas platform system design help improv diabet manag
compani boehring ingelheim modern allianc focu combin expertis invest
continu develop commerci jardianc type diabet heart failur chronic
kidney diseas trajenta basaglar remain part allianc primari respons develop
commerci led innov compani boehring ingelheim continu strateg lead trajenta
lilli basaglar
fourth quarter world-wide revenu billion increas percent compar
fourth quarter increas revenu driven percent increas due volum partial off-set
percent decreas due lower realiz price
revenu increas percent billion increas volum percent partial off-set
lower realiz price increas volum key growth product includ trulic taltz verzenio
jardianc emgal basaglar partial off-set decreas volum ciali due loss patent
exclus lower volum forteo well impact product withdraw lartruvo
revenu outsid increas percent billion driven increas volum percent
primarili key growth product includ trulic olumi taltz verzenio jardianc partial off-set
decreas volum strattera due loss patent exclus impact product withdraw
lartruvo addit revenu outsid benefit mileston bayer consum ag result
exclus develop commerci licens vitrakvi increas revenu due volum
partial off-set unfavor impact foreign exchang rate lower realiz price
gross margin increas percent billion fourth quarter compar fourth quarter
gross margin percent revenu percent decreas percentag point compar
fourth quarter decreas gross margin percent
primarili due unfavor product mix unfavor effect foreign exchang rate intern
inventori sold higher intang amort expens impact lower realiz price revenu
total oper expens fourth quarter defin sum research develop
market sell administr expens increas percent billion compar fourth
quarter research develop expens increas percent billion percent
revenu driven higher develop expens late-stag asset market sell administr
expens remain rel flat billion lower spend late life-cycl product on-going cost
contain measur off-set increas expens recent launch product
acquir in-process research develop charg fourth quarter fourth
quarter compani recogn acquir in-process research develop charg million
transact dicerna pharmaceut technolog chugai
pharmaceut hydra bioscienc
fourth quarter compani recogn asset impair restructur special charg
million charg primarili relat decis close sell research develop
facil locat unit kingdom well sever cost incur result action taken reduc
compani cost structur fourth quarter compani recogn asset impair restructur
special charg million primarili associ sever cost incur result action
taken reduc compani cost structur
oper incom fourth quarter billion compar million fourth quarter
increas oper incom primarili driven lower acquir in-process research develop
charg higher gross margin partial off-set higher research develop expens
incom million fourth quarter compar million fourth quarter
increas incom primarili driven gain sale compani antibiot busi
china higher net gain invest secur partial off-set charg relat repurchas debt
effect tax rate percent fourth quarter contain net discret tax benefit
includ tax benefit capit loss disposit subsidiari stock fourth quarter
compani record incom tax benefit million despit earn million incom incom
tax incom tax benefit primarili due tax reform adjust million
busi develop
fourth quarter net incom earn per share billion respect
compar net incom billion earn per share fourth quarter
increas net incom fourth quarter primarili driven higher oper incom higher
incom partial off-set higher incom tax addit increas net incom earn per share
fourth quarter significantli benefit lower weighted-averag share outstand result
elanco exchang offer share repurchas
non-gaap basi fourth-quart gross margin increas percent billion compar
fourth quarter gross margin percent revenu percent decreas percentag point
decreas gross margin percent primarili due unfavor product mix unfavor effect foreign
exchang rate intern inventori sold impact lower realiz price revenu
oper incom non-gaap basi increas million percent billion fourth quarter
compar fourth quarter due higher gross margin partial off-set higher research
incom non-gaap basi million fourth quarter compar million
fourth quarter increas incom primarili due higher net gain invest
secur higher net foreign currenc gain partial off-set higher net interest expens
effect tax rate non-gaap basi percent fourth quarter compar
percent fourth quarter lower effect tax rate fourth quarter driven primarili
increas net discret tax benefit
non-gaap basi fourth quarter net incom increas percent billion
earn per share increas percent compar billion respect fourth
quarter increas net incom driven primarili higher incom higher oper
incom increas earn per share driven primarili increas net incom lesser
extent benefit lower weighted-averag share outstand result share repurchas non-gaap
weight averag share outstand period reduc approxim million share
retir elanco exchang offer
full year world-wide revenu increas percent compar billion revenu
increas driven percent increas due volum partial off-set percent decreas due lower
realiz price percent decreas due unfavor impact foreign exchang rate
revenu increas percent billion driven increas volum key growth product
includ trulic taltz verzenio jardianc emgal basaglar increas revenu partial off-set
decreas volum product lost exclus primarili ciali well impact product
withdraw lartruvo lower volum forteo exclud ciali volum grew percent
increas revenu neg impact lower realiz price sever product primarili trulic
revenu outsid increas percent billion due increas volum key growth product
includ trulic olumi taltz jardianc verzenio increas revenu partial off-set
unfavor impact foreign exchang rate lesser extent lower realiz price
gross margin increas percent billion gross margin percent revenu percent
increas percentag point compar increas gross margin percent primarili due
favor impact foreign exchang rate intern inventori sold lower intang amort
expens partial off-set unfavor product mix impact lower realiz price revenu charg
result product withdraw lartruvo
total oper expens defin sum research develop market sell
administr expens increas percent billion research develop expens
increas percent billion percent revenu driven higher late-stag develop
expens market sell administr expens increas percent billion primarili due
increas market expens recent launch product partial off-set lower expens late life-cycl
compani recogn acquir in-process research develop charg million result
busi develop transact ac immun centrexion therapeut immunext avid
bioscienc compani recogn acquir in-process research develop charg
billion primarili relat acquisit armo bioscienc busi develop transact
compani recogn asset impair restructur special charg million
charg primarili associ acceler vest loxo oncolog employe equiti award part
close acquisit loxo oncolog lesser extent charg associ decis
close sell research develop facil locat unit kingdom compani recogn
asset impair restructur special charg million primarili associ asset
impair relat sale posilac rbst brand augusta georgia manufactur site
charg also includ expens associ effort reduc compani cost structur
oper incom increas percent compar billion driven primarili lower
acquir in-process research develop lesser extent higher gross margin partial off-set higher
incom million compar million increas incom
primarili driven higher net gain invest secur gain sale compani antibiot
busi china partial off-set charg relat repurchas debt higher net interest expens
full year effect tax rate percent compar effect tax rate percent
full year higher effect tax rate primarili due non-deduct acquir in-process
research develop charg
full year net incom earn per share billion respect compar
billion respect increas net incom earn per share
driven primarili gain recogn disposit elanco well higher oper incom
addit increas net incom earn per share significantli benefit lower weighted-
averag share outstand result elanco exchang offer share repurchas
non-gaap basi full year gross margin increas percent billion compar
full year gross margin percent revenu full year percent compar
percent full year
oper incom non-gaap basi decreas million percent billion driven higher
oper expens partial off-set higher gross margin
incom non-gaap basi million full year compar million full
year increas incom primarili due higher net gain invest secur partial
off-set higher net interest expens
effect tax rate non-gaap basi percent full year compar percent
full year lower effect tax rate driven primarili increas net discret tax benefit
result resolut certain global incom tax audit
non-gaap basi net incom increas percent earn per share increas percent
billion respect increas net incom driven primarili lower tax expens higher
incom partial off-set lower oper incom increas earn per share driven
increas net incom well benefit lower weighted-averag share outstand result share
repurchas non-gaap weight averag share outstand period reduc
approxim million share retir elanco exchang offer
fourth-quart world-wide trulic revenu billion increas percent compar
fourth quarter revenu increas percent million driven increas demand partial
off-set lower realiz price trulic lower realiz price primarili due chang segment
mix increas coverag gap fund requir medicar part higher contract rebat partial off-set
chang estim rebat discount revenu outsid million increas
percent driven increas volum partial off-set unfavor impact foreign exchang rate lower
full year world-wide trulic revenu billion increas percent compar
full year revenu increas percent billion driven higher demand partial off-set lower
realiz price revenu outsid increas percent million primarili driven increas
volum partial off-set unfavor impact foreign exchang rate lesser extent lower realiz
fourth quarter world-wide humalog revenu decreas percent compar fourth quarter
million revenu increas percent million driven primarili increas
volum higher realiz price due segment mix revenu outsid decreas percent
million primarili driven decreas volum lesser extent unfavor impact foreign exchang
full year world-wide humalog revenu decreas percent billion compar full year
 humalog revenu billion percent decreas primarili driven lower realiz
price decreas demand humalog revenu outsid billion percent decreas primarili
driven unfavor impact foreign exchang rate
fourth quarter world-wide alimta revenu decreas percent compar fourth quarter
million revenu decreas percent million primarili driven lower realiz price
due chang estim rebat discount partial off-set increas demand revenu outsid
 decreas percent million primarili driven lower realiz price partial off-set increas
full year world-wide alimta revenu decreas percent billion compar full year
 alimta revenu billion percent increas driven increas demand partial
off-set lower realiz price alimta revenu outsid million percent decreas driven
lower realiz price lesser extent unfavor impact foreign exchang rate lower volum
result entri gener pemetrex germani
fourth quarter world-wide teo revenu decreas percent compar fourth quarter
million revenu decreas percent million primarili driven decreas
demand revenu outsid decreas percent million primarili driven decreas volum
lesser extent lower realiz price
full year world-wide teo revenu decreas percent billion compar full year
 forteo revenu million percent decreas primarili driven decreas
demand forteo revenu outsid million percent decreas driven decreas volum
lesser extent unfavor impact foreign exchang rate lower realiz price
compani expect volum declin forteo result competit dynam entri
gener biosimilar competit follow loss patent exclus third quarter
japan major european market
fourth quarter world-wide taltz revenu increas percent compar fourth quarter
million revenu increas percent million driven increas demand partial
off-set lower realiz price due unfavor segment mix revenu outsid increas percent
million primarili driven increas volum recent launch partial off-set lower realiz price
unfavor impact foreign exchang rate
full year taltz gener world-wide revenu billion increas percent compar
full year revenu billion increas percent primarili driven increas demand
partial off-set lower realiz price revenu outsid million increas percent
driven increas volum recent launch partial off-set unfavor impact foreign exchang
fourth quarter world-wide humulin revenu increas percent compar fourth quarter
million revenu increas percent million driven increas volum higher
realiz price due chang estim rebat discount revenu outsid increas percent
million due higher realiz price increas volum partial off-set unfavor impact
full year world-wide humulin gener revenu billion decreas percent compar
full year revenu million percent decreas driven lower realiz price
partial off-set increas volum revenu outsid million percent decreas primarili
driven unfavor impact foreign exchang rate partial off-set increas volum lesser
fourth quarter world-wide basaglar revenu increas percent compar fourth quarter
million revenu increas percent million driven higher realiz price
lesser extent increas demand revenu outsid increas percent million driven
increas volum partial off-set lower realiz price unfavor impact foreign exchang rate
basaglar part compani allianc boehring ingelheim lilli report total sale basaglar
revenu payment made boehring ingelheim portion gross margin report cost sale
full year basaglar gener world-wide revenu billion increas percent
compar full year revenu million increas percent driven higher
realiz price increas demand revenu outsid million increas percent
driven increas volum partial off-set unfavor impact foreign exchang rate lesser
compani world-wide jardianc revenu fourth quarter million increas
percent compar fourth quarter revenu increas percent million driven
increas demand revenu outsid million increas percent driven increas
volum partial off-set unfavor impact foreign exchang rate jardianc part compani
allianc boehring ingelheim lilli report revenu portion jardianc gross margin
full year world-wide jardianc revenu million increas percent compar
full year revenu increas percent million driven increas demand revenu outsid
 increas percent million primarili driven increas volum partial off-set
unfavor impact foreign exchang rate
fourth quarter world-wide cyramza revenu million increas percent compar
fourth quarter revenu million increas percent primarili driven
increas demand revenu outsid million increas percent primarili driven
full year world-wide cyramza revenu million increas percent compar
full year revenu increas percent million driven increas demand lesser
extent higher realiz price revenu outsid increas percent million primarili due
increas volum partial off-set unfavor impact foreign exchang rate lower realiz price
fourth quarter world-wide ciali revenu decreas percent compar fourth quarter
million revenu million fourth quarter percent decreas compar
fourth quarter driven decreas demand due gener competit revenu outsid
decreas percent million driven unfavor impact foreign exchang rate partial off-set
full year world-wide ciali revenu decreas percent million compar full year
 ciali revenu million percent decreas driven decreas demand due
gener competit ciali revenu outsid million percent decreas driven
unfavor impact foreign exchang rate lower volum due loss exclus europ lesser
fourth quarter verzenio gener world-wide revenu million increas million
compar third quarter revenu million increas million compar
third quarter primarili driven increas demand revenu outsid million
increas million compar third quarter
full year verzenio gener world-wide revenu million revenu increas
percent compar full year million driven increas demand lesser extent
higher realiz price revenu outsid million driven higher volum recent
fourth quarter olumi gener world-wide revenu million revenu
million revenu outsid million increas percent compar fourth quarter
driven increas demand partial off-set lower realiz price unfavor impact foreign
full year olumi gener world-wide revenu million increas million
compar full year revenu million revenu outsid increas percent
million driven increas volum partial off-set unfavor impact foreign exchang rate
lesser extent lower realiz price
fourth quarter emgal gener world-wide revenu million increas million
compar third quarter revenu million increas million compar
third quarter primarili driven increas demand revenu outsid million
fourth quarter
full year emgal gener world-wide revenu million revenu million
revenu outsid million
compani updat certain element financi guidanc report basi non-gaap
basi reflect pend acquisit dermira report basi earn per share
expect rang non-gaap basi compani re-affirmed earn per share
rang
compani anticip revenu billion billion revenu growth still expect
driven volum key growth product includ trulic taltz basaglar jardianc verzenio cyramza
olumi emgal baqsimi expect launch reyvowtm revenu growth could also benefit
addit qbrexza revenu pend acquisit dermira well potenti launch new
medicin revenu growth expect partial off-set lower revenu product lost patent
exclus includ expect entri gener competit forteo revenu growth also
expect partial off-set low-singl digit net price declin driven primarili rebat
legisl increas medicar part cost share patient afford program net price declin china
japan europ
gross margin percent revenu still expect approxim percent report basi
approxim percent non-gaap basi
market sell administr expens expect rang billion billion
research develop expens still expect rang billion billion
oper margin percentag defin oper incom percent revenu expect
approxim percent report basi still expect percent non-gaap basi
incom expens still expect expens rang million million
effect tax rate still expect approxim percent report basi non-gaap
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
lilli found colonel eli lilli man commit creat high-qual medicin met real need
era unreli elixir peddl question charact charg gener employe
follow take find make better better
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
compani take toughest health challeng treat diseasesw aim make
remark impact peopl live highli focus research-driven biopharmaceut
today employe around world focu deliv transform medicin therapi
allergan plc nyse agn headquart dublin ireland global pharmaceut leader focus
develop manufactur commerci brand pharmaceut devic biolog surgic regen
medicin product patient around world
one world largest pharmaceut servic compani serv unit state
canada select global market focu pharmaceut suppli channel servic
pharmaceut manufactur healthcar provid compani servic solut rang nich premium
logist pharmaceut packag reimburs pharmaceut consult servic scale
posit healthcar industri valu bring channel help busi continu
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
global science-l biopharmaceut busi innov medicin use million
time world around us chang burden diseas increas respond
increas focu growth innov patient-centr technolog digit
data advanc cutting-edg scienc
bausch health compani inc formerli valeant pharmaceut multi-national specialti pharmaceut
compani base laval canada bausch health focus improv peopl live health care
product deliv commit patient health care provid stakehold societi
build innov compani dedic advanc global health
baxter touch live million peopl around world everi day product therapi found
throughout hospit clinic er pharmaci icu well advanc patient
care home inc fortun american health care compani headquart
bristol-my squibb differenti compani led uniqu biopharma strategi leverag reach
resourc major pharma compani pair entrepreneuri spirit agil biotech firm work
everi day deliv innov medicin patient seriou life-threaten diseas
consid founder industri genentech member roch group deliv
promis biotechnolog year
genentech biotechnolog compani dedic pursu groundbreak scienc discov develop
medicin peopl seriou life-threaten diseas transform discoveri includ first
target antibodi cancer first medicin primari progress multipl sclerosi
science-l global healthcar compani special purpos help peopl feel better live
glaxosmithklin plc form result merger glaxo wellcom plc smithklin
beecham plc although histori trace back year london plough court pharmaci
johnson johnson believ good health foundat vibrant live thrive commun forward
progress that year aim keep peopl well everi age everi stage
life today world largest broadli base healthcar compani commit use reach
size good strive improv access afford creat healthier commun put healthi
mind bodi environ within reach everyon everywher
johnson johnson incorpor state new jersey
era unpreced complex healthcar patient care mani
organ deliv care need get much healthier
vision improv care everi set one product one partner one patient time
make happen everi day touch virtual everi aspect healthcar
global healthcar compani histori work make differ
make differ live peopl global innov medicin vaccin anim health
product commit premier research-intens biopharmaceut compani dedic
provid lead innov solut today futur
discov develop provid innov product servic save improv live around world
novarti creat merger ciba-geigi sandoz novarti predecessor compani
trace root back year rich histori develop innov product
purpos reimagin medicin improv extend peopl live use innov scienc
technolog address societi challeng healthcar issu discov develop breakthrough
treatment find new way deliv mani peopl possibl also aim reward
invest money time idea compani
novo nordisk drive chang defeat diabet seriou chronic condit
novo nordisk global healthcar compani year innov leadership diabet care
heritag given us experi capabl also enabl us help peopl defeat seriou chronic
condit rare bleed disord growth hormon relat disord obes
headquart denmark novo nordisk employ approxim peopl countri market
product countri
start humbl begin year ago rural michigan today one largest
luther perrigo owner gener store apple-dri busi idea packag
distribut patent medicin household item countri store luther launch privat label concept
way enhanc custom loyalti addit cost offer imprint store name label
epsom salt sweet oil bay rum dozen wet dri good stock gener store
pfizer inc research-bas global biopharmaceut compani appli scienc global resourc
bring therapi peopl extend significantli improv live discoveri develop
manufactur healthcar product global portfolio includ medicin vaccin well mani
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
field human health undergo profound scientif technolog chang point way major
therapeut innov patient
sanofi innov dna mission har new technolog new way work find
healthcar solut around world research develop strategi innov view
three angl scienc technolog digit
build strong global footprint size scale teva reaffirm commit place peopl
center strategi enabl mani possibl live better healthier day develop
produc market afford high qualiti gener drug well innov specialti pharmaceut
activ pharmaceut ingredi
biopharmaceut compani across america peopl go work everi day mission advanc
innov treatment cure make differ million patient live
commit ensur patient access medicin preserv strong economi support vibrant
research valuabl job also stand behind medicin creat valu provid
patient across health care system
new era medicin breakthrough scienc transform care approach treat
patient robust invest research develop biopharmaceut compani result
advanc discoveri unlik anyth weve seen applic genom develop person
medicin enabl physician tailor treatment uniqu need patient immunotherapi
har patient immun system fight variou condit includ cancer rare diseas
last decad alon biopharmaceut compani invest half trillion dollar invest
begin yield result open door entir new way tackl complex difficult
treat diseas time
progress see today revolution treat diseas save patient live improv qualiti life
public health across broad rang chronic rare condit new era medicin mani diseas
previous regard deadli manag potenti curabl today medicin
clinic develop around world across medicin pipelin clinic develop
potenti first-in-class treatment repres entir new approach treat diseas futur
never brighter research explor new frontier year ago may regard
scienc fiction transform patient live
new era medicin isnt good news healthit good news health care system societi
new innov medicin keep patient healthi hospit reduc need costli emerg
room visit hospit stay surgeri long-term care save money patient nation health
system look forward medicin best bet confront countri biggest health cost driver chronic
diseas condit cancer diabet heart diseas lead caus death disabl
unit state patient condit account health care spend iv continu
advanc treatment indispens address societi health econom challeng year
invest biopharmaceut innov improv save live also drive tremend contribut
american economi america role leader medic innov biopharmaceut
compani invest billion unit state industri america
industri support million job across countri employe across compani
go work everi day research develop new treatment cure patient occur even face
continu setback develop timelin extens cost high rate scientif
new medicin transform care patient fight debilit diseas like cancer hepat heart diseas
mani rare condit yet midst progress spend retail physician-administ medicin
continu repres overal health care spend next decad mani new medicin
revolution care patient yet spend medicin project continu remain small stabl
share health care spend occur market-bas system unit state promot
incent continu innov increas patient access need medicin leverag competit
control cost
 market highli competit robust competit brand gener andincreasinglybiosimilar
altern result medicin price fall dramat competit occur among brand name medicin
price fall even gener introduc market fact prescript fill patient
unit state gener typic cost fraction price initi brand medicin ix expect
dynam continu year ahead sinc billion brand sale project face gener
biosimilar competit
anoth reason current marketplac medicin success control cost health insur
pharmaci benefit manag pbm power sophist purchas use leverag negoti
discount rebat list price medicin today top three pbm manag
prescript fill unit state xi averag list price medicin given
rebat discount insur compani govern pbm entiti suppli chain often
requir larg rebat medicin cover xii fact evid suggest negoti discount rebat
price concess doubl sinc total billion
continu growth rebat discount keep prescript medicin price growth slowest rate
year doesnt feel way mani patient often negoti save make way
patient increasingli ask pay pocket innov medicin unlik care receiv
in-network hospit physician offic patient high deduct coinsur pay cost share base
list price medicin even though insur may receiv steep discount half commerci
insur patient out-of-pocket spend brand medicin base full list price xiv mean patient
high deduct health plan pay list price month medicin may pay hundredsor even
thousandsmor year insur pay medicin
insur increasingli expos patient list price medicin patient seen out-of-pocket cost
continu grow pharmaci commerci insur patient deduct seen out-of-pocket
cost brand medicin increas sinc
though rebat discount grown substanti health plan typic use portion negoti
rebat reduc premium enrolle rather directli lower cost patient face high cost-shar
due deduct coinsur creat system payer requir patient pay pocket
rebat save spread among health plan enrolle form lower premium ask sicker
patient subsid premium healthier enrolle exact opposit health insur suppos
chang need ensur billion negoti rebat discount price concess
use lower cost patient pharmaci counter research show high cost share associ
lower medic adher increas abandon rate put patient abil stay need
therapi risk share negoti discount could save certain commerci insur patient high deduct
coinsur annual increas premium less xx medicar
part polici ensur save negoti discount pass medicar beneficiari would also
improv afford senior strengthen competit incent part program exampl typic
medicar beneficiari diabet take five medicin could save year out-of-pocket cost
america biopharmaceut compani commit work policymak stakehold advanc
market-bas solut aim toward ensur patient access need treatment support continu
innov drive valu health care system address misalign suppli chain incent
statu quo work patient misalign incent health care system need chang
rebat price concess payer receiv biopharmaceut compani use lower
cost share patient pharmaci counter need improv afford predict
cost senior medicar part current limit out-of-pocket expens adopt out-
of-pocket cap medicar part would align benefit commerci insur market ensur
beneficiari face catastroph ill abl afford treatment provid patient
transpar medicin cost phrma member voluntarili direct patient link cost inform
direct-to-consum dtc televis advertis phrma also launch medicin assist tool
provid link referenc dtc televis advertis help patient connect financi assist
make medicin afford move toward health care system focus result measur
valu eye patient enabl privat sector develop new better way pay
medicin move toward value-driven health care system includ develop data provid
patient physician easy-to-us inform differ medicin work creation better measur
qualiti care take account patient feel reform allow new way insur pay
medicin advanc research method relat valu assess encompass outcom
matter patient famili import step toward goal
commit advanc market-bas reform promot competit modern drug discoveri
develop process get medicin approv effici ensur safeti need modern
drug discoveri develop process equip regul new technolog expertis keep
centuri scienc also need ensur time review approv gener biosimilar medicin
patient benefit less expens gener biosimilar medicin replac treatment follow expir
patent data protect addit unit state must continu incentiv medic innov
competit strong intellectu properti incent enforc within outsid unit
market-bas health care system work well control cost done help work even
better patient current system creat misalign incent pbm other suppli chain
favor medicin high list price rebat impact patient afford reform need
prevent pbm other suppli chain paid list price medicin instead fee base
valu servic provid wrong way address misalign incent greater govern
intervent marketplac negoti adopt harm practic countri restrict patient
access need medicin strengthen health care system must also address misalign profit incent
fuel hospit markup medicin provid consolid address misalign incent
present opportun reduc largest fastest contributor health care costshospit spend
pharmaceut research manufactur america phrma
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
